Clinical Trial Update: Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer [Phase 3]

View source ↗

Summary

Ongoing Phase 3 trial evaluating pembrolizumab with radiotherapy for oligometastatic head and neck squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Oligometastatic Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Status: RECRUITING